Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Diabetic Macular Edema
NCT03097068Phase 4Completed
- Sponsor
- Vitreo Retinal Associates
- Start
- Apr 2017
- Primary completion
- Dec 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in diabetic macular edema (DME), sponsored by Vitreo Retinal Associates. Primary endpoint: Vascular Endothelial Growth Factor at 12 weeks. Started Apr 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03097068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097068.